Additional file 4 of Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

Abstract

Additional file 4: Figure S1. Stratified analysis in patients with different histologies who carried alterations with different actionability levels. A. Subgroup of lung adenocarcinoma: PFS and OS in patients carrying level 1-2 alterations treated with a matched therapy and a nonmatched therapy. B. Subgroup of lung adenocarcinoma: PFS and OS in patients carrying level 3-4 alterations treated with a matched therapy and a nonmatched therapy. C. Subgroup of other NSCLC histologies: PFS and OS in patients carrying level 1-2 alterations treated with a matched therapy and a nonmatched therapy. D. Subgroup of other NSCLC histologies: PFS and OS in patients carrying level 3-4 alterations treated with a matched therapy and a nonmatched therapy